Defining 'Substantial Efficacy': Post Hoc Analysis OK (When FDA Does It)
Executive Summary
Agency's interpretation of four unsuccessful trials of Fabre-Kramer's antidepressant seems like 'cherry picking' and could create an uneven playing field for sponsors, some advisory committee members say; nevertheless, panel overwhelmingly concludes efficacy was lacking.